This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Surks, M. I. Articles by Daniels, G. H. Search for Related Content PubMed PubMed Citation Articles by Surks, M. I. Articles by Daniels, G. H. Related Collections Neuroendocrinology and Pituitary Thyroid

The Thyrotropin Reference Range Should Remain Unchanged

Division of Endocrinology and Metabolism, Department of Medicine (M.I.S., G.G.), and Department of Pathology (M.I.S.), Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York 10467; and Thyroid Unit and Department of Medicine, Massachusetts General Hospital and Harvard Medical School (G.H.D.), Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Dr. Martin I. Surks, Division of Endocrinology and Metabolism, Montefiore Medical Center, 111 East 210th Street, Bronx, New York 10467. E-mail: msurks{at}westnet.com.

Context: Recent recommendations to decrease the upper limit of the TSH reference range from 4.5 to 2.5 mIU/liter, based on the high proportion of normal people whose serum TSH is less than 2.5 mIU/liter and the observation that those with TSH between 2.5 and 4.5 mIU/liter [upper reference range (URR)] have increased risk of progression to overt hypothyroidism (Whickham, 20-yr data), have not been subjected to critical analysis.

Study Subjects: The study subjects were from the Reference Group of NHANES III, 14,333 people more than 12 yr old, without known thyroid disease or antithyroid antibodies; 85% had TSH levels below 2.5 mIU/liter, and 2.3% had subclinical hypothyroidism (SCH). An additional 9.7% had URR TSH, representing 20.6 million Americans, who would also be identified as SCH if the upper TSH limit were decreased. Many with URR TSH do not have thyroid disease.

Intervention: The time of phlebotomy is important, because the TSH level varies throughout the day, with early morning values greater than later ones, and is accentuated by sleep deprivation, strenuous exercise, or working during the night or evening shifts. Repeated measurements in the same individual vary considerably over months.

Results: About half of those with URR TSH probably have thyroid disease, but most with thyroid disease, antithyroid peroxidase antibodies, have TSH below 2.5 mIU/liter. Those with URR TSH with thyroid disease probably have minimal thyroid deficiency, without any reported adverse health consequences or benefit of treatments with levothyroxine.

Conclusion: Because routine levothyroxine treatment is not recommended for SCH, it is certainly not warranted in individuals with URR TSH. For all patients with URR TSH, it is reasonable to determine serum TSH every 1–2 yr.

This article has been cited by other articles:

				T. E. Hamilton, S. Davis, L. Onstad, and K. J. Kopecky Thyrotropin Levels in a Population with No Clinical, Autoantibody, or Ultrasonographic Evidence of Thyroid Disease: Implications for the Diagnosis of Subclinical Hypothyroidism J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1224 - 1230. [Abstract] [Full Text] [PDF]

				B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]

				V. Fatourechi Upper Limit of Normal Serum Thyroid-Stimulating Hormone: A Moving and Now an Aging Target? J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4560 - 4562. [Full Text] [PDF]

				M. I. Surks and J. G. Hollowell Age-Specific Distribution of Serum Thyrotropin and Antithyroid Antibodies in the U.S. Population: Implications for the Prevalence of Subclinical Hypothyroidism J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4575 - 4582. [Abstract] [Full Text] [PDF]

				C. A. Spencer, J. G. Hollowell, M. Kazarosyan, and L. E. Braverman National Health and Nutrition Examination Survey III Thyroid-Stimulating Hormone (TSH)-Thyroperoxidase Antibody Relationships Demonstrate That TSH Upper Reference Limits May Be Skewed by Occult Thyroid Dysfunction J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4236 - 4240. [Abstract] [Full Text] [PDF]

				J. Meyerovitch, P. Rotman-Pikielny, M. Sherf, E. Battat, Y. Levy, and M. I. Surks Serum Thyrotropin Measurements in the Community: Five-Year Follow-up in a Large Network of Primary Care Physicians Arch Intern Med, July 23, 2007; 167(14): 1533 - 1538. [Abstract] [Full Text] [PDF]

				B. O. Asvold, T. Bjoro, T. I. L. Nilsen, and L. J. Vatten Association between Blood Pressure and Serum Thyroid-Stimulating Hormone Concentration within the Reference Range: A Population-Based Study J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 841 - 845. [Abstract] [Full Text] [PDF]

				E. Ortega, N. Pannacciulli, C. Bogardus, and J. Krakoff Plasma concentrations of free triiodothyronine predict weight change in euthyroid persons Am. J. Clinical Nutrition, February 1, 2007; 85(2): 440 - 445. [Abstract] [Full Text] [PDF]

				B. O Asvold, L. J Vatten, T. I L Nilsen, and T. Bjoro The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study Eur. J. Endocrinol., February 1, 2007; 156(2): 181 - 186. [Abstract] [Full Text] [PDF]

				E. Jensen, O. Blaabjerg, P. H. Petersen, and L. Hegedus Sampling Time Is Important but May Be Overlooked in Establishment and Use of Thyroid-Stimulating Hormone Reference Intervals Clin. Chem., February 1, 2007; 53(2): 355 - 356. [Full Text] [PDF]

				B. M. Casey and K. J. Leveno Thyroid disease in pregnancy. Obstet. Gynecol., November 1, 2006; 108(5): 1283 - 1292. [Abstract] [Full Text] [PDF]

				J. P. Walsh, L. C. Ward, V. Burke, C. I. Bhagat, L. Shiels, D. Henley, M. J. Gillett, R. Gilbert, M. Tanner, and B. G. A. Stuckey Small Changes in Thyroxine Dosage Do Not Produce Measurable Changes in Hypothyroid Symptoms, Well-Being, or Quality of Life: Results of a Double-Blind, Randomized Clinical Trial J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2624 - 2630. [Abstract] [Full Text] [PDF]

				W. Teng, Z. Shan, X. Teng, H. Guan, Y. Li, D. Teng, Y. Jin, X. Yu, C. Fan, W. Chong, et al. Effect of iodine intake on thyroid diseases in China. N. Engl. J. Med., June 29, 2006; 354(26): 2783 - 2793. [Abstract] [Full Text] [PDF]

				G Brabant, P Beck-Peccoz, B Jarzab, P Laurberg, J Orgiazzi, I Szabolcs, A P Weetman, and W M Wiersinga Is there a need to redefine the upper normal limit of TSH? Eur. J. Endocrinol., May 1, 2006; 154(5): 633 - 637. [Abstract] [Full Text] [PDF]